share_log

Despite Delivering Investors Losses of 57% Over the Past 3 Years, Micro-Tech (Nanjing)Ltd (SHSE:688029) Has Been Growing Its Earnings

Despite Delivering Investors Losses of 57% Over the Past 3 Years, Micro-Tech (Nanjing)Ltd (SHSE:688029) Has Been Growing Its Earnings

儘管在過去3年中給投資者帶來了57%的虧損,南微醫學(南京)有限公司(SHSE:688029)的收入仍在增長。
Simply Wall St ·  09/11 18:10

The truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term Micro-Tech (Nanjing) Co.,Ltd (SHSE:688029) shareholders have had a particularly rough ride in the last three year. Sadly for them, the share price is down 58% in that time.

事實上,如果你投資足夠長的時間,你會最終遇到一些虧損的股票。但是長期以來,南微醫學(南京)有限公司(SHSE:688029)的股東在過去三年中經歷了一次特別艱難的旅程。遺憾的是,在那段時間裏,股價下跌了58%。

On a more encouraging note the company has added CN¥379m to its market cap in just the last 7 days, so let's see if we can determine what's driven the three-year loss for shareholders.

更令人鼓舞的是,在過去的7天裏,公司市值增加了3,7900萬元人民幣,所以讓我們看看是什麼導致股東們在過去三年中遭受了虧損。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的話順便說一下,「船隻將環遊世界,但支持地球平面學會的人將大有可爲。 在市場上,價格和價值之間將繼續存在巨大的差異...」通過比較EPS和股價變化,我們可以了解到投資者對公司的態度隨時間的變化程度。

During the unfortunate three years of share price decline, Micro-Tech (Nanjing)Ltd actually saw its earnings per share (EPS) improve by 22% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past.

在不幸的三年股價下跌期間,南微醫學(南京)有限公司的每股收益(EPS)實際上每年提高了22%。考慮到股價的反應,有人可能會懷疑EPS不是該時期業務績效的良好指標(可能是因爲一次性損益),或者過去的增長預期可能過於不合理。

Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.

由於EPS的變化似乎與股價的變化不相關,因此值得查看其他指標。

With a rather small yield of just 1.6% we doubt that the stock's share price is based on its dividend. We note that, in three years, revenue has actually grown at a 13% annual rate, so that doesn't seem to be a reason to sell shares. It's probably worth investigating Micro-Tech (Nanjing)Ltd further; while we may be missing something on this analysis, there might also be an opportunity.

該股票的股價並不是基於其股息的相對較低的1.6%的收益率。我們注意到,過去三年,營業收入實際上以13%的年增長率增長,因此這似乎不是賣出股票的原因。或許進一步調查南微醫學(南京)有意義;雖然我們也許在這種分析中忽略了一些東西,但也可能有機會。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以看到以下收益和營收的變化情況(通過單擊圖像了解精確值)。

big
SHSE:688029 Earnings and Revenue Growth September 11th 2024
SHSE:688029盈利和營收增長2024年9月11日

We know that Micro-Tech (Nanjing)Ltd has improved its bottom line lately, but what does the future have in store? So it makes a lot of sense to check out what analysts think Micro-Tech (Nanjing)Ltd will earn in the future (free profit forecasts).

我們知道,南微醫學(南京)最近改善了其底線,但未來會產生什麼影響呢?因此,檢查一下分析師認爲南微醫學(南京)未來將獲得多少收益(免費利潤預測)是很有道理的。

A Different Perspective

不同的觀點

Micro-Tech (Nanjing)Ltd shareholders are down 18% over twelve months (even including dividends), which isn't far from the market return of -20%. Unfortunately, last year's performance is a deterioration of an already poor long term track record, given the loss of 6% per year over the last five years. Weak performance over the long term usually destroys market confidence in a stock, but bargain hunters may want to take a closer look for signs of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Micro-Tech (Nanjing)Ltd is showing 1 warning sign in our investment analysis , you should know about...

南微醫學(南京)的股東在過去十二個月中下跌了18%(包括分紅),這與市場回報率-20%差不多。不幸的是,去年的表現是已經不好的長期跟蹤記錄的惡化,因爲在過去五年中每年虧損6%。長期表現疲軟通常會摧毀對股票的市場信心,但淘寶獵人可能希望更仔細地觀察是否出現轉機的跡象。我認爲長期股價作爲業績的一個代理人是非常有趣的,但要真正獲得洞察力,我們還需要考慮其他信息。儘管如此,請注意,南微醫學(南京)在我們的投資分析中顯示了1個警告信號,你應該了解一下……

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果您像我一樣,就不會希望錯過這份免費的內部人士正在購買的低估小市值股票列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論